-
PD-L1–CMTM6 Disruption Activates Antitumor Immunity
2026-09-15
The reference study identifies PD-L1 recycling in myeloid cells as a therapeutic vulnerability and shows that the antibody H1A redirects PD-L1 toward degradation by disrupting its interaction with CMTM6. Across humanized mouse and human immune-cell models, this approach activated myeloid cells, expanded cytotoxic T-cell populations, improved tumor control, and promoted immunological memory.
-
In Vitro Drug Responses: Why Viability Metrics Matter
2026-09-15
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability when evaluating anticancer drugs in vitro, showing that growth inhibition and cell death are related but non-equivalent response dimensions. The work provides a practical framework for interpreting drug assays, especially when epigenetic or cytotoxic mechanisms may change the balance and timing of proliferation arrest versus killing.
-
Pregnancy LNP Design Shapes mRNA Potency and Safety
2026-09-14
The reference study shows that lipid nanoparticle structure and administration route jointly determine mRNA expression, inflammatory signaling, placental targeting, and maternal–fetal outcomes in pregnant mice. Its mechanistic framework is useful for designing delivery experiments and for interpreting reporter-mRNA data without treating transfection efficiency as an isolated endpoint.
-
Light-Inducible RNA Release in Gene Therapy
2026-09-14
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic gene expression at the level of translation. By combining LIRP with AAV delivery and light-accessible tissues, the authors demonstrate controllable therapeutic activity in obesity and retinal neovascular disease models, while identifying important requirements for clinical translation.
-
T-5224: C-Fos/AP-1 Inhibitor Workflows
2026-09-13
Use T-5224 to separate c-Fos/c-Jun transcriptional activity from broader inflammatory signaling in arthritis, osteoclastogenesis, and emerging neuroinflammation assays. This practical guide covers solvent handling, dose-finding, pathway controls, readouts, and limitations when extending the compound toward trigeminal pain research.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-09-12
The reference study identifies Cdc2-like kinase 2 (CLK2) as a mediator of platinum resistance in ovarian cancer and links its activity to BRCA1 Ser1423 phosphorylation and DNA damage repair. Its tissue, cellular, and xenograft evidence supports CLK2 as a mechanistic target, while also highlighting the need to distinguish CLK2-specific biology from broader Clk-family and splicing effects.
-
FH1 Workflow for iPS-Derived Hepatocyte Maturation
2026-09-12
Learn how FH1 (Catalog No. B3700) can strengthen iPS cell differentiation to hepatocytes by improving albumin output, CYP3A4 expression, colony morphology, and AFP-associated maturity readouts. This practical guide covers dosing pilots, assay design, storage, troubleshooting, and how to interpret FH1-enabled hepatocyte-like cell cultures in translational liver research.
-
3-(1-methylpyrrolidin-2-yl)pyridine (N2703) Workflows
2026-09-11
Use N2703 as a defined chemical comparator for nicotine-pathway reconstruction, LC-MS validation, and carefully controlled cellular perturbation assays. Its high aqueous and organic-solvent compatibility supports flexible workflows, while the latest biosynthesis findings help researchers distinguish endpoint formation from precursor transport and compartmentation.
-
Hydroxytyrosol in Nicotine-CKD Assay Design
2026-09-11
Hydroxytyrosol can help researchers dissect redox and inflammatory responses in nicotine-linked kidney injury models. This article translates nicotine-CKD evidence into a controlled assay framework while defining what the current evidence can—and cannot—support.
-
Annexin V-PE Apoptosis Detection Kit Guide
2026-09-10
This scenario-based guide explains how SKU K2200 can support apoptosis detection in live cells when proliferation and cytotoxicity assays produce ambiguous results. It connects phosphatidylserine externalization, flow cytometry, fluorescence microscopy, and the GANT61 ALK-positive lymphoma model with practical controls and interpretation limits.
-
CGRP/SP–Piezo2 Signaling in Trigeminal Allodynia
2026-09-10
Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and cellular experiments connect ATP, PKC, ERK1/2, p38 MAPK, Merkel cells, and trigeminal sensory neurons into a mechanistic framework for trigeminal neuralgia research.
-
Fe3O4@ZIF-8 in Jaw Osteomyelitis
2026-09-09
The reference study presents Fe3O4@ZIF-8 core–shell nanoparticles as a dual-function platform for jaw osteomyelitis, combining pH-responsive Zn2+ release for antibacterial activity with Fe3O4- and magnetic-field-associated support for bone regeneration. Its principal contribution is a materials strategy that addresses persistent infection and infected bone defects within one treatment concept, while also identifying bacterial membrane disruption and heat shock dysregulation as relevant antibacterial mechanisms.
-
T-5224: AP-1 Inhibition Workflows
2026-09-09
T-5224 is a selective C-Fos/AP-1 inhibitor for separating AP-1-dependent inflammatory, osteoclastogenic, and cancer-cell responses from broader transcriptional effects. This practical guide covers formulation, cell-based assay design, arthritis workflows, ferroptosis-oriented validation, and troubleshooting.
-
SB-3CT Workflows for MMP-2/MMP-9 Research
2026-09-08
SB-3CT is a mechanism-based gelatinase inhibitor for separating MMP-2 and MMP-9 contributions in tumor invasion, angiogenesis, and extracellular-matrix remodeling. This workflow connects practical enzyme, cancer, perineuronal-net, and cerebral-ischemia assays while emphasizing dose selection, controls, and interpretation limits.
-
T-5224: Practical C-Fos/AP-1 Inhibition Workflows
2026-09-08
T-5224 is a selective C-Fos/AP-1 inhibitor for separating AP-1-driven cytokine, matrix-remodeling, and osteoclastogenic responses from broader transcriptional effects. This workflow connects validated arthritis research applications with a carefully bounded assay strategy for testing c-Jun-linked inflammation in bacteria–tumor models.